Dr Reddy partners with UCB to distribute Briviact in India

Dr. Reddy Laboratories informed the bourses that it has entered into a distribution and co-promotion agreement for Briviact, a brand of brivaracetam with UCB. This agreement will provide Dr. Reddy right to exclusively distribute Briviact in the Indian market.

Briviact is generally used as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients. The medication is prescribed for patients above 16 years of age.

Dr. Reddy Laboratories is the second largest pharma company in India in revenue terms. Its Q4FY18 revenue mix comprises of Global Generics (75 per cent), Pharmaceutical services & active ingredients (21 per cent), Proprietary products (2 per cent) and others (1 per cent).

During FY18, the company has a good filings performance of 19 ANDA & 1 NDA filed in US. Also, 107 ANDAs and 3 NDAs are pending for approval. Also, it has launched 15 new products in North America in FY18 and has entered into more new markets in LatAm, Africa and Asia.

On Monday, the stock opened at Rs. 2,272.10 and jumped by 2.76 per cent and made an intraday high of Rs. 2,335 and finally closed at Rs. 2,329, on the BSE.